These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 26249841)

  • 41. The effects of liraglutide on both hypereosinophilic insulin allergy and the characteristics of anti-insulin antibodies in type 2 diabetes mellitus: a case report.
    Hirai H; Ogata E; Kikuchi N; Kohno T; Machii N; Hasegawa K; Watanabe T; Satoh H
    J Med Case Rep; 2016 Jul; 10():202. PubMed ID: 27456688
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A software interface for in silico testing of type 2 diabetes treatments.
    Visentin R; Cobelli C; Dalla Man C
    Comput Methods Programs Biomed; 2022 Aug; 223():106973. PubMed ID: 35792365
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Increment of C-peptide after glucagon injection determines the progressive nature of Japanese type 2 diabetes: a long-term follow-up study.
    Fukui T; Oono K; Hara N; Yamamoto T; Nagashima M; Naito H; Hirano T
    Endocr J; 2013; 60(6):715-24. PubMed ID: 23386398
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Defining criteria for the introduction of liraglutide using the glucagon stimulation test in patients with type 2 diabetes.
    Kondo Y; Satoh S; Nagakura J; Kimura M; Nezu U; Terauchi Y
    J Diabetes Investig; 2013 Nov; 4(6):571-5. PubMed ID: 24843711
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Analysis of factors influencing pancreatic beta-cell function in Japanese patients with type 2 diabetes: association with body mass index and duration of diabetic exposure.
    Funakoshi S; Fujimoto S; Hamasaki A; Fujiwara H; Fujita Y; Ikeda K; Hamamoto Y; Hosokawa M; Seino Y; Inagaki N
    Diabetes Res Clin Pract; 2008 Dec; 82(3):353-8. PubMed ID: 18950889
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Liraglutide is effective in type 2 diabetic patients with sustained endogenous insulin-secreting capacity.
    Kozawa J; Inoue K; Iwamoto R; Kurashiki Y; Okauchi Y; Kashine S; Kitamura T; Maeda N; Okita K; Iwahashi H; Funahashi T; Imagawa A; Shimomura I
    J Diabetes Investig; 2012 Jun; 3(3):294-7. PubMed ID: 24843579
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treating with liraglutide an obese patient with type 2 diabetes mellitus and hereditary hemochromatosis.
    Tassone F; Baffoni C; Gianotti L; Pellegrino M; Magro G; Cesario F; Maccario M; Borretta G
    Minerva Endocrinol; 2015 Dec; 40(4):331-2. PubMed ID: 25801016
    [No Abstract]   [Full Text] [Related]  

  • 48. MR Assessed Changes of Renal Sinus Fat in Response to Glucose Regulation in West European and South Asian Patients With Type 2 Diabetes.
    Lin L; Dekkers IA; Tao Q; Paiman EHM; Bizino MB; Jazet IM; Lamb HJ
    J Magn Reson Imaging; 2024 Aug; 60(2):729-738. PubMed ID: 38085104
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oral glucose-stimulated serum C-peptide predicts successful switching from insulin therapy to liraglutide monotherapy in Japanese patients with type 2 diabetes and renal impairment.
    Araki H; Tanaka Y; Yoshida S; Morita Y; Kume S; Isshiki K; Araki S; Uzu T; Kashiwagi A; Maegawa H
    J Diabetes Investig; 2014 Jul; 5(4):435-41. PubMed ID: 25411603
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Real-World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada.
    Wharton S; Liu A; Pakseresht A; Nørtoft E; Haase CL; Mancini J; Power GS; Vanderlelie S; Christensen RAG
    Obesity (Silver Spring); 2019 Jun; 27(6):917-924. PubMed ID: 31062937
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gluco-regulation & type 2 diabetes: entrenched misconceptions updated to new governing principles for gold standard management.
    Schwartz SS; Herman ME
    Front Endocrinol (Lausanne); 2024; 15():1394805. PubMed ID: 38933821
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Residual endogenous insulin secretion in Japanese children with type 1A diabetes.
    Sugihara S; Kikuchi T; Urakami T; Yokota I; Kikuchi N; Kawamura T; Amemiya S;
    Clin Pediatr Endocrinol; 2021; 30(1):27-33. PubMed ID: 33446949
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association learning is impaired in insulin resistance and restored by liraglutide.
    Nat Metab; 2023 Aug; 5(8):1262-1263. PubMed ID: 37596351
    [No Abstract]   [Full Text] [Related]  

  • 54. A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2).
    Nomoto H; Miyoshi H; Furumoto T; Oba K; Tsutsui H; Miyoshi A; Kondo T; Tsuchida K; Atsumi T; Manda N; Kurihara Y; Aoki S;
    PLoS One; 2015; 10(8):e0135854. PubMed ID: 26284918
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Retrospective analysis of safety and efficacy of liraglutide monotherapy and sulfonylurea-combination therapy in Japanese type 2 diabetes: Association of remaining β-cell function and achievement of HbA1c target one year after initiation.
    Usui R; Yabe D; Kuwata H; Murotani K; Kurose T; Seino Y
    J Diabetes Complications; 2015; 29(8):1203-10. PubMed ID: 26279320
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial.
    Tanaka K; Saisho Y; Manesso E; Tanaka M; Meguro S; Irie J; Sugiura H; Kawai T; Jinzaki M; Cobelli C; Itoh H;
    Clin Drug Investig; 2015 Oct; 35(10):675-84. PubMed ID: 26369653
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and Clinical Characteristics of Liraglutide in Japanese Patients With Type 2 Diabetes.
    Ito D; Iuchi T; Kurihara S; Inoue I; Katayama S; Inukai K
    J Clin Med Res; 2015 Sep; 7(9):694-9. PubMed ID: 26251684
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.
    Smits MM; Tonneijck L; Muskiet MH; Kramer MH; Pouwels PJ; Pieters-van den Bos IC; Hoekstra T; Diamant M; van Raalte DH; Cahen DL
    Diabetologia; 2016 Dec; 59(12):2588-2593. PubMed ID: 27627981
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis.
    Fisher M; Petrie MC; Ambery PD; Donaldson J; Ye J; McMurray JJ
    Lancet Diabetes Endocrinol; 2015 Sep; 3(9):697-703. PubMed ID: 26276240
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists.
    Uccellatore A; Genovese S; Dicembrini I; Mannucci E; Ceriello A
    Diabetes Ther; 2015 Sep; 6(3):239-56. PubMed ID: 26271795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.